116 related articles for article (PubMed ID: 10500777)
21. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
Laredo J; Huynh A; Muller C; Jaffrézou JP; Bailly JD; Cassar G; Laurent G; Demur C
Blood; 1994 Jul; 84(1):229-37. PubMed ID: 7912555
[TBL] [Abstract][Full Text] [Related]
22. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
Bailly JD; Muller C; Jaffrézou JP; Demur C; Gassar G; Bordier C; Laurent G
Leukemia; 1995 May; 9(5):799-807. PubMed ID: 7769842
[TBL] [Abstract][Full Text] [Related]
23. Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis.
Kuwazuru Y; Yoshimura A; Hanada S; Ichikawa M; Saito T; Uozumi K; Utsunomiya A; Arima T; Akiyama S
Br J Haematol; 1990 Jan; 74(1):24-9. PubMed ID: 1968762
[TBL] [Abstract][Full Text] [Related]
24. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells.
den Ouden D; van den Heuvel M; Schoester M; van Rens G; Sonneveld P
Leukemia; 1996 Dec; 10(12):1930-6. PubMed ID: 8946933
[TBL] [Abstract][Full Text] [Related]
25. Discordance of P-glycoprotein expression and function in acute leukemia.
De Moerloose B; Dhooge C; Philippé J
Adv Exp Med Biol; 1999; 457():107-18. PubMed ID: 10500786
[TBL] [Abstract][Full Text] [Related]
26. Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.
Nüssler V; Gieseler F; Zwierzina H; Gullis E; Pelka-Fleischer R; Diem H; Abenhardt W; Schmitt R; Langenmayer I; Wohlrab A; Kolb HJ; Wilmanns W
Ann Hematol; 1997 Feb; 74(2):57-64. PubMed ID: 9063374
[TBL] [Abstract][Full Text] [Related]
27. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia.
van den Heuvel-Eibrink MM; Wiemer EA; de Boevere MJ; van der Holt B; Vossebeld PJ; Pieters R; Sonneveld P
Blood; 2001 Jun; 97(11):3605-11. PubMed ID: 11369657
[TBL] [Abstract][Full Text] [Related]
28. Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells.
Zhou DC; Simonin G; Faussat AM; Zittoun R; Marie JP
Leukemia; 1997 Sep; 11(9):1516-22. PubMed ID: 9305607
[TBL] [Abstract][Full Text] [Related]
29. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
30. MDR1/P-GP expression as a prognostic factor in acute leukemias.
Marie JP; Legrand O
Adv Exp Med Biol; 1999; 457():1-9. PubMed ID: 10500774
[TBL] [Abstract][Full Text] [Related]
31. Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blast crisis.
Lee EJ; Schiffer CA; Tomiyasu T; Testa JR
Leukemia; 1990 May; 4(5):350-3. PubMed ID: 2388480
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase.
List AF; Kopecky KJ; Willman CL; Head DR; Slovak ML; Douer D; Dakhil SR; Appelbaum FR
Blood; 2002 Sep; 100(5):1910-2. PubMed ID: 12176916
[TBL] [Abstract][Full Text] [Related]
33. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Chiodini B; Bassan R; Barbui T
Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
[TBL] [Abstract][Full Text] [Related]
34. High expression of interleukin-2 receptor α-chain (CD25) in myelodysplastic syndrome preceding acute myeloid leukemia and chronic myeloid leukemia in myeloid blast crisis.
Nakase K; Kita K; Kyo T; Katayama N
Leuk Lymphoma; 2017 May; 58(5):1268-1270. PubMed ID: 27736287
[No Abstract] [Full Text] [Related]
35. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
36. Expression of the multidrug transporter P-glycoprotein and in vitro chemosensitivity: correlation with in vivo response to chemotherapy in acute myeloid leukemia.
Chitnis M; Hegde U; Chavan S; Juvekar A; Advani S
Sel Cancer Ther; 1991; 7(4):165-73. PubMed ID: 1687990
[TBL] [Abstract][Full Text] [Related]
37. Anthracyclines, proteasome activity and multi-drug-resistance.
Fekete MR; McBride WH; Pajonk F
BMC Cancer; 2005 Sep; 5():114. PubMed ID: 16159384
[TBL] [Abstract][Full Text] [Related]
38. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
39. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
40. New developments in the treatment of acute myeloid leukemia.
Smeets M; de Witte T; van der Lely N; Raymakers R; Muus P
Adv Exp Med Biol; 1999; 457():557-65. PubMed ID: 10500834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
